CINECA IRIS Institutional Research Information System

To determine the clinical activity and safety of the combination immunotherapy of the chimeric anti-CD20 antibody, Rituximab, and Interferon (IFN)- alpha 2a

Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma

SAGLIO, Giuseppe;
2001-01-01

Abstract

To determine the clinical activity and safety of the combination immunotherapy of the chimeric anti-CD20 antibody, Rituximab, and Interferon (IFN)- alpha 2a
2001
HAEMATOLOGICA
86
9
951
958
Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon-alpha; Italy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins; Recurrence; Rituximab; Safety; Treatment Outcome
Sacchi, S; Federico, M; Vitolo, U; Boccomini, C; Vallisa, D; Baldini, L; Petrini, M; Rupoli, S; Di Raimondo, F; Merli, F; Liso, V; Tabilio, A; Saglio, G; Vinci, G; Brugiatelli, M; Dastoli, G
03A-Articolo su Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1592735
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 63
social impact